Zacks Investment Research on MSN9d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
Nasdaq4d
Is the Future Bleak for SAVA Stock Following Another Setback?
Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...
Nasdaq9d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second ...